Kaoru Kubota - Researcher Profile | RDL Research Database

Publications

2 shown

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok , Yi‐Long Wu , Iveta Kudaba +97 more

2019 The Lancet 3175 citations

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Scott Antonia , Augusto Villegas , Davey B. Daniel +30 more

Durvalumab therapy resulted in significantly longer overall survival than placebo. No new safety signals were identified. (Funded by AstraZeneca; PACIFIC ClinicalTrials.gov numb...

2018 New England Journal of Medicine 2682 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 5,857
Institution: Nippon Medical School Hospital

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0003-0367-2606

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.